Hytera to Officially Launch LTE-PMR Convergence Solution at CCW2017
11.5.2017 09:25:00 EEST | Business Wire | Press release
Hytera, a world leading solution provider and innovator of Professional Mobile Radio (PMR) communications, will officially launch its highly-anticipated innovative LTE-PMR convergence solution at the Critical Communications World (CCW) 2017 to be held at Asia World Expo during May 16-18 in Hong Kong. Hytera LTE-PMR convergence solution comprises cutting-edge Multi-mode Advanced Radio, narrowband-broadband convergent infrastructure and management software.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170510006802/en/
Hytera Global Summit 2017 (Graphic: Business Wire)
"This will be another milestone for Hytera and the PMR industry. Hytera once again brings its own answer to the users, and presents a clear path of adopting feature-rich broadband technologies, while emphasizing irreplaceable voice services made reliably accessible by narrowband technologies such as TETRA, DMR and PDT," said Yelin Jiang, Vice President of Hytera.
A Hytera global summit themed as “Innovative Convergence” is to be held on May 16th, the first day of CCW2017, before the exhibition opens its show floor. It will admit Hytera’s invited users and partners, as well as CCW visitors who have registered with Hytera. The summit will be held in Room 201 at Asia World Expo, from 2:00PM to 4:00PM.
As the biggest exhibitor of CCW2017, besides its LTE-PMR convergence solution Hytera will also showcase a series of narrowband-based innovations including DMR and Tetra terminal and infrastructure. The new generation of Command & Control Centre will also be the highlight of the booth demonstrating Hytera's increasing capability of integration and innovation in developing up-to-date solution for the users of mission and business critical industries.
Hytera Global Summit 2017
May 16th, 2017
2:00PM-4:00PM
Room
201, 2F, Asia World Expo
Registration Portal-
ccw.hytera.com
Hytera @ CCW2017
May 16th-18th, 2017
Hall
3, Booth C8
About CCW
Critical Communications World is the leading and most influential congress and exhibition dedicated to connecting critical communications professionals for three days of thought provoking discussion, debate and networking.
About Hytera Communications
Hytera Communications Corporation Limited, a world leading solution provider and innovator of Professional Mobile Radio (PMR) communications, is dedicated to improving organizational efficiency and making the world safer with technical innovations. Established in 1993 in Shenzhen, China, Hytera Communications is the second-largest PMR provider in the world, the world’s fastest-growing PMR solution provider, and the world’s #1 DMR Tier III Trunking provider. Hytera serves customers in over 120 countries and regions, including government, public security, utility, transportation, enterprise and businesses. In 2011, Hytera became a publicly-listed company in China, trading on the Shenzhen Stock Exchange (SHE: 002583). Hytera’s market capitalization has grown 500% by the end of 2016.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170510006802/en/
Contact information
Hytera Communications Corporation Limited
Media Enquiry
Johnny
Jian, +86 755 26972999
johnny.jian@hytera.com
www.hytera.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom